Top Page
IRLAB Therapeutics AB Class A
(IRLAB.A)
IRLAB Therapeutics AB Class A (IRLAB.A) vs. iShares MSCI Sweden ETF (EWD)
IRLAB Therapeutics AB Class A Business Overview & Revenue Model
IRLAB Therapeutics AB Class A Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 75.74M | 94.63M | 5.68M | 61.14M | 207.78M | 300.00K |
| Gross Profit | -21.65M | -92.42M | -122.73M | -111.23M | 168.69M | -1.70M |
| EBITDA | -80.37M | -68.07M | -173.32M | -109.13M | 55.37M | -89.46M |
| Net Income | -103.34M | -83.13M | -177.84M | -114.20M | 51.78M | -91.85M |
Balance Sheet | ||||||
| Total Assets | 116.50M | 136.21M | 177.12M | 323.56M | 472.45M | 370.07M |
| Cash, Cash Equivalents and Short-Term Investments | 53.64M | 66.92M | 111.31M | 252.78M | 401.90M | 277.01M |
| Total Debt | 75.76M | 60.42M | 27.57M | 3.98M | 6.60M | 2.93M |
| Total Liabilities | 144.18M | 103.58M | 61.36M | 32.72M | 72.97M | 22.19M |
| Stockholders Equity | -27.68M | 32.63M | 115.76M | 290.83M | 399.48M | 347.88M |
Cash Flow | ||||||
| Free Cash Flow | -63.98M | -65.79M | -165.14M | -145.99M | 127.93M | -89.61M |
| Operating Cash Flow | -63.78M | -65.59M | -164.85M | -142.61M | 128.64M | -89.21M |
| Investing Cash Flow | -199.00K | -199.00K | -293.00K | -3.38M | -708.00K | -394.00K |
| Financing Cash Flow | 19.35M | 21.40M | 23.68M | -3.13M | -3.04M | 256.09M |
IRLAB Therapeutics AB Class A Technical Analysis
IRLAB Therapeutics AB Class A Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | kr299.95M | ― | -56.75% | ― | ― | 53.88% | |
| ― | €298.01M | ― | ― | ― | 1192.39% | 23.82% | |
| ― | €209.37M | -1.29 | -199.86% | ― | 69.03% | 23.10% | |
| ― | kr193.96M | ― | -69.22% | ― | ― | -56.68% | |
| ― | €194.86M | ― | -402.04% | ― | ― | 27.61% |
IRLAB Therapeutics AB Class A Corporate Events
IRLAB Therapeutics AB announced a presentation and webcast for its Q3 2025 interim report, scheduled for October 29, 2025. The event will feature insights from CEO Kristina Torfgård and EVP Nicholas Waters, focusing on the company’s financial performance and ongoing research developments. This announcement highlights IRLAB’s commitment to transparency and stakeholder engagement, potentially impacting its market positioning and investor relations.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics has appointed Gustaf Albèrt as the new Chief Financial Officer, effective November 17, 2025. Albèrt brings extensive experience from senior financial roles in the biotech sector, including positions at Isofol Medical and Aqilion. His appointment is expected to bolster IRLAB’s management team as the company continues its focus on value creation and advancing its pipeline of Parkinson’s disease treatments.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics announced that CEO Kristina Torfgård will present at the Redeye Theme: Neurology event in Stockholm, providing an opportunity to engage with Swedish and international investors. This presentation could enhance IRLAB’s network and potentially lead to new collaborations, reinforcing its position in the neurology sector.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB has announced a significant advancement in its development of the drug candidate IRL757, aimed at treating apathy in Parkinson’s disease. In partnership with the McQuade Center for Strategic Research and Development, LLC (MSRD), IRLAB has secured a $4 million investment to progress IRL757 into a Phase Ib clinical study. This study will assess the drug’s safety, tolerability, and potential efficacy in patients with Parkinson’s disease who experience apathy. The move is based on promising preclinical and Phase I study results, highlighting IRL757’s unique mechanism in reversing nerve signaling disruptions associated with apathy. This development positions IRLAB as a potential leader in addressing a significant unmet need in the treatment of apathy, impacting millions globally.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics has been granted a new patent in China for the salt form of its leading drug candidate, mesdopetam, which is under development for treating levodopa-induced dyskinesias in Parkinson’s disease patients. This patent extension enhances the market exclusivity of mesdopetam, potentially extending its protection into the mid-2040s, thereby increasing its value and strengthening IRLAB’s position in major markets, including the USA, Europe, and Japan.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB announced an increase in the number of shares and votes due to a rights issue resolved by the Board of Directors. As of August 29, 2025, the total number of shares is 84,938,020, with an equal number of votes, indicating a strategic move to potentially enhance capital and shareholder value.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB announced a new patent for Mesdopetam, enhancing its US patent protection and extending it into the 2040s. The company also reported positive Phase I results for IRL757, supporting its ongoing development. Despite a decrease in net sales and operating profit, a rights issue raised SEK 115.7 million, bolstering the company’s financial position.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB announced a presentation and webcast for their Q2 2025 interim report, scheduled for August 27, 2025. The report will be discussed by key executives, providing insights into the company’s financial performance and ongoing projects, potentially impacting stakeholder perceptions and industry positioning.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB has appointed Roy Jonebrant as interim CFO, effective September 1, 2025, following the departure of Viktor Siewertz. Jonebrant brings extensive experience in financial management within the life sciences sector, which is expected to benefit IRLAB during its search for a permanent CFO. This leadership change is significant for IRLAB as it continues to advance its pipeline of Parkinson’s disease treatments.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
IRLAB Therapeutics AB has successfully registered a rights issue, converting paid subscribed shares into regular shares, raising approximately SEK 115.7 million before costs. This financial move is expected to bolster the company’s operations, potentially enhancing its market position and offering reassurance to stakeholders about its ongoing development projects.
IRLAB Therapeutics announced the departure of their CFO, Viktor Siewertz, who has been instrumental in the company’s growth and development over the past decade. His exit marks a significant change in the company’s leadership as they begin the search for a new CFO, potentially impacting their strategic direction and stakeholder confidence.